SAILIFE.NS

T2Emerging Markets (IEMG)

Sai Life Sciences Limited

Next est. report · AMC

Loading…
Loading chart…
Key Reported Metrics, Reratings Triggers & Results3 rows

EBITDA growth demonstrates the company's operational efficiency and profitability amidst substantial capital expenditure. Expanding margins are key for investor

Last reported · 2026-11-05

Key reported metricsRerating thresholds
MetricLast periodWhy it mattersWhat's needed for reratingRerating contextEarnings date
EBITDA Growth18% YoY

EBITDA growth demonstrates the company's operational efficiency and profitability amidst substantial capital expenditure. Expanding margins are key for investor confidence, especially as Sai Life Sciences scales its manufacturing capacity and aims for its long-term margin targets.

EBITDA Growth of 35%+ YoY for the upcoming 2026-11-05 earnings report.

EBITDA growth above 35% YoY, significantly higher than the last reported 18% YoY, would showcase strong operating leverage and efficiency. This indicates effective management of increased capital expenditure and progress towards the 28-30% long-term EBITDA margin targets, boosting investor confidence.

CDMO Revenue Growth6% YoY

As a CRDMO with significant investments in manufacturing, particularly for new modalities like peptides, CDMO revenue growth is vital. It signals the company's ability to convert its pipeline into commercial production and capitalize on the growing demand in the pharmaceutical outsourcing market.

CDMO Revenue Growth of 25%+ YoY for the upcoming 2026-11-05 earnings report.

Achieving 25%+ YoY CDMO revenue growth, a significant acceleration from the last reported 6% YoY, is crucial. It would demonstrate successful conversion of pipeline into commercial production, capitalize on the rapidly expanding GLP-1 and peptide CDMO market, and justify substantial manufacturing capacity investments.

Total Revenue Growth12% YoY

This metric reflects the overall demand for Sai Life Sciences' integrated CRDMO services. Sustained growth indicates successful client engagement and market penetration, crucial for validating its expansion strategy and achieving long-term guidance.

Total Revenue Growth of 20%+ YoY for the upcoming 2026-11-05 earnings report.

Exceeding 20% YoY revenue growth, above the company's 15-20% long-term CAGR guidance and recent Q1 FY27 performance of 12% YoY, would validate Sai Life Sciences' expansion strategy and market penetration, signaling robust demand for its integrated CRDMO services.

NotesTable
DateCommentComment TypeComment SentimentLinkPrice Reaction
2026-11-05Sai Life Sciences reported strong Q2 FY27 results with 23% YoY revenue growth and 28% EBITDA growth, driven by healthy CRO and CDMO segments. The market reacted very positively, with the stock gaining 10.10% post-earnings, significantly outperforming SPY. This reflects investor confidence in robust operational performance, new strategic pharma partnerships, and maintained long-term guidance, despite minor capacity deferrals. Analysts largely hold 'Strong Buy' ratings.Earnings TranscriptPositive+10.10% (vs SPY: +7.41%)